Fig. 3From: miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimodROC curves for 548a-3p expression levels in the Discovery (Cohort 1) and Validation cohort (Cohort 2). ROC curve for NEDA-3 vs EDA-3 regarding miR-548a-3p in the Discovery (A) and Validation (B) cohortBack to article page